Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > End of August

<< Previous

Bullboard Posts

Next >>

Comment by RPINVESTOR1on Aug 19, 2023 9:54pm

124 Views

Post# 35596688

RE:RE:RE:RE:RE:RE:RE:End of August

To me, Shiseido has been playing games with Replicel. Although Replicel may generally know what type of information they should receive in the event of a favourable decision, Shiseido may withhold
some additional data and claim that they have provided all of the information. I have no confidence that Shiseido will act in good faith.

<< Previous

Bullboard Posts

Next >>

Nintendo stock jumps despite Q2 financials, new console news